Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma

Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma

Summary: EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) have achieved clinical success in lung adenocarcinoma (LUAD). However, tumors often show profound but transient initial response and then gain resistance. We identify transcription factor ZNF263 as being significantly decreased in osimer...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Jiaqi Liang, Guoshu Bi, Qihai Sui, Guangyin Zhao, Huan Zhang, Yunyi Bian, Zhencong Chen, Yiwei Huang, Junjie Xi, Yu Shi, Qun Wang, Cheng Zhan
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Elsevier 2024-02-01
Cyfres:Cell Reports
Pynciau:
CP: Cancer
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S2211124724000998

Rhyngrwyd

http://www.sciencedirect.com/science/article/pii/S2211124724000998

Eitemau Tebyg